IMMUNOGENICITY | An Initiative of ILS and BIRAC

IMMUNOGENICITY FACILITY

(An Initiative of ILS and BIRAC)

ILS Bhubaneswar has established a state-of-the-art clinical immunogenicity assay platform to facilitate SARS-CoV-2 related clinical investigations and vaccine development with the help of DBT-BIRAC. The facility will provide services for testing and validation of vaccine efficacy and safety against SARS-CoV-2 in human subjects on a fee-for-service basis.

We have developed standard operating procedures and advanced instrumentation facility for sensitive, precise and reproducible test results.

Current status of No. of assays and individuals
@ Immunogenicity Assay Platform

No. of tests with various variants of SARS-CoV-2

COVID-RBD specific antibody profiling in infected patients,
direct contacts and controls

Longitudinal profiling of COVID-RBD IgG antibodies in COVID
vaccinated subjects

Pseudo-virus neutralization activity using serum of COVID
infected patients, their direct contacts and controls

Cytokine profiling of COVID infected patients infected patients,
their direct contacts and controls

Outline depicting T-cell profiling from COVID-19 vaccinated
subjects

IMMUNOGENICITY ASSAY FACILITY

IMMUNOGENICITY FACILITY

(An Initiative of ILS and BIRAC)

Current status of No. of assays and individuals @ Immunogenicity Assay Platform

No. of tests with various variants of SARS-CoV-2

COVID-RBD specific antibody profiling in infected patients, direct contacts and controls

Longitudinal profiling of COVID-RBD IgG antibodies in COVID vaccinated subjects

Pseudo-virus neutralization activity using serum of COVID infected patients, their direct contacts and controls

Cytokine profiling of COVID infected patients infected patients, their direct contacts and controls

Outline depicting T-cell profiling from COVID-19 vaccinated subjects